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ABSTRACT 
  Trans-10, cis-12 conjugated linoleic acid (CLA) is a fatty acid intermediate 
produced during rumen biohydrogenation of dietary polyunsaturated fatty acids in the 
cow. Trans-10, cis-12 CLA inhibits de novo milk fat synthesis in the mammary gland 
through a coordinated downregulation of key lipogenic enzymes and the nuclear protein 
thyroid hormone responsive spot 14 (S14). A previous study using a mouse model 
showed that the S14 knockout (KO) mouse was hyperresponsive to CLA. In KO mice, 
mammary lipogenesis decreased by 82% in response to a 5-day treatment of 20 mg/d 
trans-10, cis-12 CLA, whereas in wildtype (WT) controls, rates of lipogenesis decreased 
by 23%. The objective of the present study was to investigate whether the KO mouse was 
also hypersensitive to CLA. This was done by testing the lactogenic response of the KO 
mice to a low dose of CLA. WT and KO C57BL/6J mice were orally administered with 
either water (control) or 3.5 mg/d of trans-10, cis-12 CLA for 5 days. In response to CLA 
treatment, KO dams had a 28.7% reduction in the percentage of de novo synthesized fatty 
acids in milk, whereas in WT dams this reduction (8.9%) was not significant, and there 
was an interaction of genotype and CLA treatment. Investigations with mammary 
explants demonstrated that lipogenic capacity decreased in both KO and WT dams, but 
there was no interaction of genotype and CLA treatment. A compilation of results from 
the present study and from previous studies suggests that the ED50 of CLA of the WT and 
KO mice are similar, thus indicating that the sensitivity of the two genotypes are similar.  
Therefore, the S14 KO mouse is hyperresponsive to CLA-induced inhibition of 
mammary lipogenesis but sensitivity is unaltered.  iii 
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INTRODUCTION 
  Milk fat depression (MFD) is a common economic problem in today’s dairy 
industry and it represents a dietary situation in which the fat content in cow’s milk is 
reduced. MFD is associated with certain diets including ones high in polyunsaturated fat 
and highly digestible carbohydrate. The biohydrogenation theory established that MFD is 
caused by an inhibition of milk fat synthesis in the mammary gland by specific bioactive 
fatty acids produced as intermediates in ruminal biohydrogenation (Bauman and Griinari, 
2003). Trans-10, cis-12 conjugated linoleic acid (CLA) was the first of these 
biohydrogenation intermediates specifically identified to reduce milk fat synthesis and 
has been examined in the context of nutrigenomics, the study of the effect of specific 
bioactive dietary components on gene expression. Trans-10, cis-12 CLA has been shown 
to cause a coordinated downregulation in the gene expression of key lipogenic enzymes, 
thus resulting in reduced milk fat. Specifically, the sterol response element binding 
protein (SREBP) transcription factor signaling system and the nuclear protein thyroid 
hormone responsive spot 14 (S14) have been implicated (Harvatine and Bauman, 2006).  
Further investigation of the mechanism of CLA-induced MFD has been possible 
using a lactating mouse model developed in our laboratory.  In this mouse model of MFD, 
oral administration of trans-10, cis-12 CLA results in a dose-dependent reduction in milk 
fat, a shift in milk fatty acid profile, and a downregulation of mammary gene expression 
of lipogenic enzymes much like in the dairy cow. In addition, a functional role of S14 in 
CLA-induced MFD has been recently demonstrated during CLA treatment of S14 null 
mice. When treated with CLA at a dose known to induce a near maximal response in 
wildtype animals, the knockout animals decreased mammary lipogenesis by 82%, which 2 
 
is significantly greater than the 23% reduction observed in wildtype controls (Harvatine 
and Bauman, unpublished). Thus, mammary lipogenesis of S14 null mice is 
hyperresponsive to CLA at this near maximal dose. Lower CLA doses, however, have not 
been examined, and it is unknown if the S14 null mouse is also hypersensitive to CLA. 
This information would provide insight into the mechanism of the CLA-induced 
inhibition of milk fat synthesis. The objective of this thesis is to examine the sensitivity 
of the S14 knockout mice to CLA by testing the lactogenic response to a low dose of 
CLA.  3 
 
REVIEW OF THE LITERATURE  
 
Milk fat 
Milk fat accounts for a large proportion of the energy in milk and is also the most 
variable milk component. Although reduced fat milk is increasingly desired for 
consumption as fluid milk, other dairy products such as cheese and ice cream require 
high levels of milk fat. Therefore, from a production standpoint, fat content affects the 
economic value of milk.  
Ruminant milk is estimated to contain over 400 different fatty acids (Bauman and 
Griinari, 2001). The two sources of fatty acids in milk fat are preformed circulating fatty 
acids absorbed in the small intestine and mobilized from body reserves, and de novo fatty 
acids synthesized in the mammary gland. In the cow, de novo fatty acids constitute about 
half of the total fatty acids in milk fat. De novo fatty acids are short and medium chain 
fatty acids, from four to fourteen carbons in length plus ~50% of the sixteen carbon fatty 
acids. In contrast, preformed fatty acids are long chain, including the remaining portion 
of the sixteen carbon fatty acids and all the fatty acids of eighteen or more carbons. The 
fat content of milk is affected by genetics and the environment. From a managerial 
perspective, nutrition is the major environmental factor affecting milk fat and the most 
practical way of manipulating milk fat levels (Bauman and Griinari, 2003).  
 
Milk fat depression 
Milk fat depression (MFD), first described in 1885, is a phenomenon commonly 
observed in dairy cows and it represents a dietary situation in which the fat content of  4 
 
 
Figure 1. Proposed pathways of ruminal biohydrogenation of linoleic acid.  Adapted 
from Bauman and Griinari (2003). 
 
milk is reduced (Bauman and Griinari, 2003). During MFD cows do not achieve their 
genetic potential for milk fat synthesis and the value of the milk is decreased, thus 
creating an economic problem for producers. Only fat is affected in diet-induced MFD; 
milk yield and protein composition are unchanged. MFD is associated with certain diets 
including those high in polyunsaturated fat and highly fermentable carbohydrate.  
Many theories have attempted to explain the mechanism of MFD, but most have 
proven inadequate (Bauman and Griinari, 2001). Davis and Brown (1970) observed that 
changes in milk fat yield correlated with the concentration of trans fatty acids in milk. 
Milk from milk fat-depressed cows contained an increased amount of trans-C18:1 fatty 
acids. Griinari et al. (1998) later observed that not all isomers of trans-C18:1 fatty acids 
correlated with low milk concentration. Rather, a specific increase in trans-10 C18:1 and 
its rumen precursor, trans-10, cis-12 conjugated linoleic acid (CLA), was seen in reduced 
fat milk. A putative pathway for ruminal biohydrogenation of dietary linoleic acid was 
proposed (Figure 1; Bauman and Griinari 2003). Linoleic acid is normally isomerized to 
cis-9, trans-11 CLA, which in turn is saturated to trans-11 C18:1 then to stearic acid. 5 
 
However, under certain dietary conditions, linoleic acid may follow an alternate pathway, 
in which isomerization to trans-10, cis-12 CLA occurs first, followed by hydrogenation 
to trans-10 C18:1 then to stearic acid. This alternate pathway has been supported by 
studies with cultures of rumen bacteria which demonstrated the production of trans-10, 
cis-12 CLA from linoleic acid (Wallace et al., 2007) and trans-10 C18:1 from trans-10, 
cis-12 CLA (Kepler et al., 1966).  
Based on this putative rumen biohydrogenation pathway, the biohydrogenation 
theory was proposed, which states that MFD is caused by an inhibition of milk fat 
synthesis in the mammary gland by specific bioactive fatty acids produced as 
intermediates in ruminal biohydrogenation (Bauman and Griinari, 2003). Trans-10, cis-
12 CLA was the first of these biohydrogenation intermediates specifically demonstrated 
to inhibit milk fat synthesis. Abomasal infusion of a mixture of CLA isomers including 
trans-10, cis-12 CLA resulted in a 55% reduction of milk fat yield (Chouinard et al., 
1999). Subsequent studies found that the trans-10, cis-12 CLA was the isomer 
responsible for the decrease in milk fat (Baumgard et al., 2000). The major CLA isomer 
in milk, cis-9, trans-11 CLA, was found to have no effect on milk fat yield in this study. 
Two more CLA isomers have been identified which inhibit milk fat synthesis, cis-10, 
trans-12 CLA (Saebo et al., 2005) and trans-9, cis-11 CLA (Perfield et al., 2007).  
A change in fatty acid composition occurs in both diet-induced and CLA-induced 
MFD. The yield of fatty acids of all chain lengths is decreased, but the reduction of de 
novo fatty acids is most prominent (Bauman and Griinari, 2003). This results in a 
decreased proportion of de novo fatty acids and an increased proportion of preformed 
fatty acids in milk fat. MFD is also associated with a decrease in stearoyl CoA desaturase 6 
 
(SCD) activity. SCD is an enzyme that introduces a cis-9 double bond in fatty acids. The 
desaturase index, the substrate/product ratio often used as a proxy for SCD activity, is 
increased for fatty acids of several lengths, including C14/C14:1, C16/C16:1, C18/C18:1 
(Baumgard et al., 2001). High CLA doses lower the desaturase index, but low CLA doses 
do not alter this index.  
 
Biological effects of trans-10, cis-12 CLA 
Conjugated linoleic acids (CLA) are fatty acids with an 18-carbon chain and a 
pair of conjugated double bonds, which are two double bonds separated by a one single 
bond. Over 20 geometric and positional isomers of CLA exist, yet little is known about 
the biological effects of most of them (Lock and Bauman, 2004). Research on CLA has 
been done primarily using mixtures of CLA isomers, due to commercial availability and 
low cost. Studies on individual isomers of CLA has focused on two isomers, cis-9, trans-
11 CLA, which is the major isomer in ruminant products, and trans-10, cis-12 CLA. 
Trans-10, cis-12 CLA is a potent bioactive fatty acid with broad range of biological 
effects (Bhattacharya et al., 2006). These include decreased body weight gain, decreased 
body fat accretion, reduced atherogenesis, reduced tumorigenesis, improved glucose 
tolerance and insulin sensitivity, alteration of inflammatory response mediators, and 
improved bone health.  
Among the first animal studies investigating the effect of CLA on body 
composition was the one by Park et al. (1997), in which mice fed a diet containing 0.5% 
CLA had 60% lower body fat and 14% more lean body mass compared to controls. Most 
animal studies examining the antiobesity effect of CLA have found that CLA reduces 7 
 
body fat, and the trans-10, cis-12 isomer has been found to be more potent (Whigham et 
al., 2007). Studies on humans to date have used mostly mixtures of CLA isomers, with a 
few studies using pure CLA isomers, and have yielded mixed results. Nevertheless, a 
meta-analysis of 18 human trials has reported that a modest body fat reduction is seen 
with the median dose of 3.2 g/d used in the studies (Whigham et al., 2007).  
Trans-10, cis-12 CLA has also been shown to reduce in vivo tumorigenesis in 
animal models and in vitro proliferation in cell culture studies. Rats fed a diet containing 
0.5% trans-10, cis-12 CLA had 33% less premalignant lesions at 6 weeks and 35% less 
mammary tumors at 24 weeks after treatment with the carcinogen methylnitrosourea 
(MNU) compared with control rats (Ip et al., 2002). In a mouse xenograft study 
comparing the effects of the cis-9, trans-11 and trans-10, cis-12 isomers of CLA on 
mammary tumorigenesis, no effect was observed on latency and tumor growth, but both 
isomers significantly reduced metastasis (Hubbard et al., 2003). Both CLA isomers have 
also been shown to reduce growth and viability of tumor cell lines derived from the 
mammary gland, prostate, and digestive tract, though the isomers differ in their 
effectiveness (summarized in Kelley et al., 2007). A number of possible mechanisms 
through which CLA exerts these anticarcinogenic effects have been proposed, and these 
include apoptosis, increased energy expenditure, increased fat oxidation, decreased 
adipocyte size, decreased energy intake, and inhibition of enzymes involved in fatty acid 
metabolism and lipogenesis (Bhattacharya et al., 2006, Li et al., 2008). As with the 
antiobesity effect, human studies on the anticarcinogenic effect of CLA have been 
inconclusive. The majority of studies found no effect of CLA and there has been no 8 
 
published human cancer study in vivo that examined the effects of purified CLA isomers 
(Kelley et al., 2007).  
In contrast to studies examining the antiobesity and anticarcinogenic effects of 
CLA, relatively few rodent studies have been conducted on the effect of CLA on lipid 
synthesis during lactation. In a study by Ringseis et al. (2004), rats were fed a 1.47% 
CLA mixture containing 22 isomers throughout breeding, pregnancy, and lactation. 
Compared to control rats fed sunflower oil, rats fed CLA had 49% lower fatty acid 
synthase (FASN) mRNA and 51% lower lipoprotein lipase (LPL) mRNA in the 
mammary, 80% lower FASN activity in the mammary, 46% lower milk fat content, fewer 
pups per litter, lower litter weights, and lower triglyceride concentration in liver but not 
in plasma. Hayashi et al. (2007) reported that in rats fed 1.35% of a CLA mixture, milk 
fat content and pup growth were reduced by 33% and 21%, respectively. CLA decreased 
short and medium chain fatty acids in milk and activities of lipogenic enzymes such as 
FASN in mammary and liver. Taken together, the results from these studies suggest that 
dietary CLA reduces milk fat through reduced de novo fatty acid synthesis in the 
mammary and impaired uptake of preformed fatty acids from the plasma into the 
mammary gland.  
Very few studies have examined the effect of individual CLA isomers on lactation. 
In one study comparing the effects of the cis-9, trans-11 and trans-10, cis-12 isomers of 
CLA, lactating mice were fed trans-10, cis-12 CLA (0.91% of diet) or cis-9, trans-11 
CLA (0.96% of diet) from day 4 to 15 of lactation (Loor et al., 2003). Trans-10, cis-12 
CLA significantly reduced milk fat concentration, reduced litter weight by 28%, and feed 
intake by 18% compared with controls, whereas cis-9, trans-11 CLA showed a smaller 9 
 
effect. Trans-10, cis-12 CLA decreased the milk fat percentage of the sum of 12:0, 14:0, 
and 16:0 by 10.69% compared with control. Lin et al. (2004) analyzed some of the 
cellular changes that occurred in the mammary tissue obtained in the Loor et al. (2003) 
study and found both CLA isomers reduced mammary mRNA levels of acetyl CoA 
carboxylase (ACC), FASN, and SCD1, and mammary activity of ACC and SCD1. Of the 
two CLA isomers, trans-10, cis-12 caused a greater decrease in ACC activity and SCD1 
mRNA and activity. Collectively, these results suggest that trans-10, cis-12 CLA is more 
potent than the cis-9, trans-11 isomer in inhibiting de novo milk fat synthesis and that the 
mechanism involves a decrease in gene expression and activity of lipogenic enzymes in 
mammary tissue. 
 
Mechanism of CLA-induced MFD 
Trans-10, cis-12 CLA has been shown to cause a coordinated downregulation in 
the gene expression of key lipogenic enzymes in the mammary gland of the dairy cow 
during MFD (Baumgard et al., 2002, Peterson et al., 2003). Affected genes include LPL, 
fatty acid binding proteins (FABP), ACC, FASN, glycerol phosphate acyltransferase 
(GPAT), and acylglycerol phosphate acyltransferase (AGPAT).  LPL and FABP are 
involved in the uptake and transport of preformed fatty acids from the circulation. ACC 
and FASN are both involved in de novo fatty acid synthesis. ACC converts acetyl CoA 
into malonyl CoA, which in turn is incorporated into the newly forming fatty acid by 
FASN. GPAT and AGPAT are involved in triglyceride synthesis (Harvatine and Bauman, 
2006).  10 
 
The coordinated downregulation of these genes suggests a role for a global 
regulator of gene expression. The sterol response element binding protein (SREBP) 
family of transcription factors was proposed as a candidate system (Baumgard et al., 
2002). A potential role of SREBP as the global moderator of lipid synthesis during MFD 
is supported by the fact that all of the CLA-responsive genes listed above contain the 
sterol response element (SRE) in their promoter to which SREBP binds. SREBP1 and 
SREBP2 are two proteins encoded by separate genes. SREBP1 consists of two subtypes, 
SREBP1a and SREBP1c, which have differential expression in various organs 
(Shimomura et al., 1997). SREBP1c is the predominant subtype in adipose tissue and is 
highly expressed in bovine mammary tissue (Harvatine and Bauman, unpublished). 
SREBP1a is the major subtype in hepatic tissues and most cell lines. Proteolytic cleavage 
of SREBP1 releases the mature functional nuclear fragment, nSREBP. nSREBP binds to 
SRE and some E-boxes in sterol-responsive genes to promote transcription (Mater et al., 
1999).  
In bovine mammary epithelial cells treated with trans-10, cis-12 CLA, nSREBP 
level was reduced but not the amount of the precursor SREBP1, suggesting that CLA 
inhibits the proteolytic cleavage of SREBP1 (Peterson et al., 2004). In vivo, the mRNA 
level of SREBP1 was decreased during both diet-induced and CLA-induced MFD 
(Harvatine and Bauman, 2006). Enzymes involved in processing of SREBP1, including 
insulin responsive gene (INSIG) 1, INSIG 2, and SREBP cleavage activating protein 
(SCAP) were also decreased. These observations support that SREBP regulates milk fat 
synthesis during diet-induced and CLA-induced MFD. An additional protein, thyroid 
hormone responsive spot 14 (S14), was identified as a candidate regulator of CLA-11 
 
mediated inhibition of milk fat synthesis in bovine mammary epithelial cells using 
microarray analysis (Harvatine and Bauman, 2006).  
 
Thyroid hormone responsive spot 14 (S14) 
The thyroid hormone responsive spot 14 is a nuclear protein highly correlated 
with lipogenesis, but its exact biochemical functions are not known (Harvatine and 
Bauman, 2006). S14 is highly expressed in tissues which produce lipid for use as a 
metabolic fuel and in which lipogenesis is regulated by thyroid hormone and dietary 
constituents (Cunningham et al., 1998). These tissues include the liver, brown and white 
adipose tissues, and lactating mammary tissue. In contrast, S14 mRNA levels in 
nonlipogenic tissues such as brain, kidney, heart, spleen, testis, pituitary gland, and 
nonlactating mammary gland are low. Thyroid hormone regulates S14 transcription in 
lipogenic tissues. For example, in rat liver, the nuclear precursor S14 mRNA 
accumulated before mature mRNA in response to thyroid hormone (Narayan et al., 1984). 
S14 expression is not controlled by thyroid hormone in nonlipogenic tissues expressing 
thyroid hormone receptors, suggesting that other tissue-specific factors are necessary for 
S14 transcription (Jump and Oppenheimer, 1985). Dietary sucrose also increases S14 
transcription when thyroid hormone is present. Hypothyroid animals have negligible 
changes in S14 mRNA levels with sucrose gavage, but response to sucrose was restored 
when thyroid hormone was coadministered with sucrose, indicating that thyroid hormone 
and sucrose act synergistically to promote S14 transcription (Mariash et al., 1986). On 
the other hand, polyunsaturated fatty acids (PUFAs) inhibit the expression of S14 
(Cunningham et al., 1998). Rats fed a diet containing menhaden oil, which is enriched in 12 
 
long chain polyunsaturated fatty acids, exhibited a rapid and significant reduction in the 
level of S14 mRNA and S14 transcription in the liver (Jump et al., 1993). In cultured 
hepatocytes, eicosapentaenoic acid significantly reduced S14 mRNA and S14 activity.  
At a molecular level, there is evidence that S14 transcription is regulated by 
SREBP1c. nSREBP1c functionally interacts with the E-box-like sequence in the PUFA 
response region of the S14 promoter (Mater et al., 1999). Overexpression of nSREBP1c, 
but not other factors known to induce S14 activity, reduced the PUFA-mediated 
suppression of S14 expression, further supporting the direct interaction of SREBP1c and 
S14 gene. In breast cancer cells, transfection with a dominant-negative mutant of 
SREBP1c reduced the induction of S14 expression by progestin to 2.5-fold of basal level, 
while transfection with constitutively active SREBP1c caused a 330-fold increase in S14 
mRNA compared to basal level in response to progestin (Martel et al., 2006). Thus, 
progestin seems to indirectly induce S14 transcription via SREBP1c.   
  Progress in identifying the biochemical role of S14 has been limited. Using a 
yeast two-hybrid system, it was demonstrated that S14 forms homodimers, which is a 
characteristic of many transcription factors (Cunningham et al., 1997). In rat hepatocytes, 
S14 coimmunoprecipitated with a 36-kDa protein, suggesting the existence of a S14-S14-
p36 complex. Chou et al. (2007) has also suggested that S14 functions as a homodimer 
and that it interacts physically and functionally with thyroid receptor to regulate gene 
expression of malic enzyme, which is involved in de novo synthesis of long chain fatty 
acids.  Subsequent studies have suggested that S14 also interacts with Zac1, a zinc finger 
protein which regulates apoptosis and cell cycle arrest, and functions as a p53-dependent 
transcriptional coactivator of lipogenic enzymes (Chou et al. 2008).  13 
 
In humans, S14 gene is located in the 11q13 amplicon (Cunningham et al., 1998). 
This region has been implicated in body weight regulation in rodents (Taylor and Phillips, 
1996) and is also amplified in approximately 20% of breast cancers (Schuuring et al., 
1992). This amplification confers a poor prognosis, prone to recurrence, and also occurs 
more frequently in recurrent than primary tumors. Indeed, recent studies have shown that 
high expression of S14 in primary invasive mammary tumors is associated with 
recurrence whereas low expression is associated with disease-free survival (Kinlaw et al., 
2006, Wells et al., 2006). Tumor samples (n = 131) were examined and clinical outcome 
of the patients were monitored for the ensuing 3000 days. S14 was detectable in all tumor 
samples, regardless of clinical outcome. 32% of tumors with maximal S14 expression 
recurred. A significant relationship (P = 0.015) was observed between level of S14 
expression and disease-free survival. Therefore, S14 is a potential tumor marker that 
predicts aggressive tumor biology and reduced disease-free survival.  
In a recent study using breast cancer cells and liposarcoma cells, a mixture of 
CLA isomers, as well as pure cis-9, trans-11 CLA and pure trans-10, cis-12 CLA, caused 
a decrease in mRNA levels of S14 and FASN and growth inhibition (Donnelly et al., 
2009). The inhibition was fully (CLA mixture and pure trans-10, cis-12 CLA) or partially 
(pure cis-9, trans-11 CLA) rescued by palmitic acid, suggesting that the anticarcinogenic 
effect of CLA is mediated via reduced tumor lipogenesis. 
Further investigation of the role of S14 has become possible with the creation of a 
S14 knockout mouse model by Dr. Cary Mariash’s laboratory (Zhu et al., 2001). In the 
S14 null mice, the gene is deleted except for the first 21 amino acids. Lack of S14 mRNA 
in the liver of the knockout mouse validated this model. The S14 null mouse shows a 14 
 
phenotype in the mammary gland (Zhu et al., 2005). Pups nursing on S14 null dams grew 
significantly less than pups nursing on wildtype dams or heterozygous dams, regardless 
of the genotype of the pups. Milk clots from S14 null dams had 28% reduced triglyceride 
levels compared to wildtype dams. No difference in protein levels was observed. 
Lactating mammary glands of null dams contained 33% less triglycerides than wildtype 
dams, due to a decrease in medium chain fatty acids. Lipid synthesis rate in the mammary 
gland was decreased by 62% in null dams compared to wildtype dams. Thus, the 
reduction in pup growth and milk fat concentration in the S14 null dams was due to a 
decrease in de novo lipid synthesis. However, no reduction in FASN and ACC activity 
was observed. In fact, ACC activity was increased in null mice. Surprisingly, no change 
in mRNA levels of lipogenic enzymes was observed. Thus, S14 does not seem to affect 
gene expression of key lipogenic enzymes as speculated before. More recently, LaFave et 
al. (2006) has reported that malonyl-CoA is higher in the mammary gland of S14 null 
mice. A possible explanation of this result is that S14 reduces lipogenesis by regulating 
FASN activity. Thus, the authors proposed that the S14 protein may allosterically 
regulate the activity of FASN. Adult S14 null mice also exhibit resistance to diet-induced 
obesity (Anderson et al., 2009). S14 null mice had a reduced rate of weight gain as a 
result of a decrease in fat accumulation. When injected with glucose intrapenitoneally, 
S14 null mice had a significantly reduced maximal blood glucose level compared to 
wildtype mice. Similarly to this improved glucose tolerance, the knockout mice exhibited 
increased insulin sensitivity. Compared to wildtype animals, null animals had a longer 
duration of repressed blood glucose in response to insulin.  
 15 
 
Mouse model of MFD 
Our laboratory has developed a lactating mouse model (C57BL/6J) to further 
investigate the mechanism of trans-10, cis-12 CLA-induced MFD. In a dose titration 
experiment with this mouse model, lactating dams were orally dosed with 0 (control), 7, 
20, and 60 mg/d of trans-10, cis-12 CLA for 5 days starting day 6-8 of lactation 
(Harvatine and Bauman, unpublished). The 60 mg/d dose resulted in a decrease in pup 
growth, reduction in milk clot fat concentration, an increase in milk protein and a 
decrease in mammary lipogenic capacity, but did not cause a decrease in milk fat 
concentration. Thus, the 60 mg/d seemed to be suppressing overall milk synthesis and 
was deemed as not an appropriate dose to study MFD, in which only milk fat is affected. 
The 20 mg/d dose induced a maximal decrease in milk fat percent without altering 
protein concentration, suggesting that the effects were specific to milk fat synthesis. The 
20 mg/d and 7 mg/d treatments resulted in a dose-dependent reduction in milk fat, a shift 
in fatty acid profile, and a downregulation of gene expression of lipogenic enzymes much 
like in the dairy cow.  Thus, 20 mg/d was determined to be the dose that induces a near 
maximal effect of MFD in the mouse.  
  To further elucidate the role of S14 in the lactogenic response to trans-10, cis-12, 
CLA, I cooperated in a study which compared wildtype and S14 null C57BL/6J mice. 
Dams of both genotypes were randomized to receive either the control treatment (water) 
or 20 mg/d of CLA for 5 days starting days 6-8 of lactation. Milk and milk clot fat 
percent was reduced by 24.6% and 14.2%, respectively, in S14 null mice compared with 
wildtype mice. CLA treatment lowered total milk fat concentration by 12% in wildtype 
and 10% in knockout animals, and there was no interaction of genotype and CLA 16 
 
treatment. In contrast, CLA treatment decreased milk fat concentration of de novo 
synthesized fatty acids (<16 carbons) by 27% in wildtype dams and 72% in S14 null 
dams. There was a strong interaction of genotype and CLA treatment (P < 0.01) for de 
novo fatty acids, as well as for C14 and C16 desaturase indexes (P < 0.001). CLA 
treatment increased milk C14 and C16 desaturase indexes by 640 and 100%, respectively, 
in S14 null mice, but increases in the wildtype dams were only 37 and 45%, respectively. 
Mammary tissue lipogenic capacity as measured by 
14C glucose incorporation into lipids 
by tissue explants was similar between control animals of either genotype. CLA 
decreased lipogenic capacity in both genotypes, and there was a strong interaction of 
genotype and CLA (P < 0.001); CLA decreased mammary lipogenic capacity by 23% in 
wildtype dams and by 82% in S14 null dams. Overall, results indicated that the lactogenic 
response of S14 null mice to CLA was much greater compared with wildtype animals at 
this near maximal dose. These results were unexpected; previous studies have suggested 
that S14 functions as a transcriptional coactivator of lipogenic enzymes (Chou et al., 
2008), thus we were expecting that the S14 null dams would not respond to CLA. The 
hyperresponsiveness of the S14 null mouse to CLA suggests that S14 has an indirect role 
in lipogenesis, possibly by altering the response of another CLA-responsive factor. 
Although the hyperresponsiveness of the S14 null mouse at a high CLA dose has been 
observed, lower CLA doses have not been examined; thus it is unknown if the S14 null 
mouse is also more sensitive to CLA. The sensitivity of the S14 null mouse relative to the 
wildtype mouse would provide further insight into the mechanism of the CLA-induced 
inhibition of milk fat synthesis.  
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OBJECTIVE 
The objective of this thesis was to examine the sensitivity of the S14 knockout mice to 
CLA by testing the milk fat response to a low dose of CLA. 
 
 
MATERIALS AND METHODS 
 
Animals and treatments 
Experimental procedures for the present study were approved by the Cornell 
University Institutional Animal Care and Use Committee. Wildtype (WT) and S14 partial 
knockout (KO) C57BL/6J mice were obtained from Dr. Cary Mariash (University of 
Minnesota). Dr. Mariash’s group has previously reported the phenotype of the S14 KO 
mice in publications by Zhu et al. (2001 and 2005). Experimental mice were the progeny 
of heterozygous breeding pairs to ensure that the genotype of the parents did not affect 
the phenotype of the experimental animals. Genotype of the animals was determined by 
PCR using DNA extracted from tail snips of weanlings (Zhu et al., 2001). Wildtype 
females were bred to knockout males and knockout females were bred to wildtype males 
to produce heterozygous pups, thus eliminating the possible effect of pup genotype. The 
dams were subsequently housed in individual cages with free access to food and water. 
Litter size was adjusted to 6-8 pups on day 0-1 of lactation by cross-fostering to eliminate 
the effect of litter size on dam lactation. Dams were randomly assigned to one of four 
treatments in a 2x2 factorial design (genotype and CLA treatment). Dams were fed ad 18 
 
libitum a pelleted rodent diet containing 22% protein and 5% fat (diet #8640, Harlan 
Teklad, Indianapolis, IN). CLA was in free fatty acid form and contained 89.0% trans-10, 
cis-12 CLA, 2.0% linolenic acid, and <0.9% of any other individual fatty acid (Natural 
ASA, Lysaker, Norway). CLA was diluted 1:2 with oleic acid to provide a reasonable 
working volume. Mice assigned to the CLA treatment (n = 8 for WT CLA, n = 9 for KO 
CLA) were orally dosed with 3.5 mg/d of trans-10, cis-12 CLA and 7 mg/d of oleic acid 
for 5 days starting on day 6-8 of lactation, and mice in the control groups (n = 7 for WT 
CON, n = 8 for KO CON) were similarly dosed with the same volume of water. The daily 
dose was divided in three equal portions and given at 0030, 0930, and 1700 h.  
 
Data and sample collection.   
Dams, pups, and feed were weighed daily between 1300 and 1400 h, and the 
average dam weight gain, litter growth, and dam intake over the last 3 days of treatment 
were used for analysis.  After the fifth day of treatment, dams and pups were euthanized 
at 1400 h. Pups were gassed with CO2 before being euthanized by cervical dislocation. 
Milk clots were collected from the stomach of each pup, composited within each litter, 
and freeze-dried.  Dams were anaesthetized with ketamine-zylazine (1 and 0.1 mg/10 g 
body weight, respectively) then euthanized by cervical dislocation. The liver was 
removed from the dams and weighed. One #4 mammary gland from the dams was placed 
in ice-cold isotonic sucrose buffer and immediately used to determine lipogenic capacity. 
The other #4 mammary gland was snap-frozen in liquid nitrogen for gene expression 
analysis.   
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Sample analysis 
Milk clot fatty acid profile 
Milk clot samples were analyzed for fat concentration and fatty acid profile 
according to Harvatine et al. (2008). Approximately 20 mg of freeze-dried milk clot was 
weighed into an extraction tube. 250 μg of both C17:0 (triglyceride) and C19:0 (methyl 
ester) were added as internal standards. Milk clot lipids were extracted by hexane: 
isopropynol extraction according to Hara and Radin (1978).  The extracted fatty acids 
were first acid methylated overnight at 40
oC in 1% methanolic sulfuric acid and 
subsequently transmethylated. Methyl esters were quantified by gas chromatography 
using a fused-silica capillary column (CP-Sil 88; 100 m x 0.25 mm [i.d.] Varian Inc.) and 
conditions as described by Perfield et al. (2006).  Milk clot fat concentrations were 
determined based on dilution of the internal standards.   
Mammary lipogenesis assay 
Rates of incorporation of 
14C glucose into fatty acid were determined in one #4 
mammary gland according to Bauman et al. (1973) as modified by Harvatine et al. 
(2008).  Briefly, mammary tissue explants were prepared using a Stadie-Riggs hand 
microtome, and approximately 100 mg tissue explants were incubated in triplicate in a 
vial with 3 mL of a modified Krebs-Ringer bicarbonate buffer at physiological pH.  Vials 
were gassed with a mixture of O2:CO2 (95:5), sealed, and incubated for 3 h at 37
o C in a 
shaking water bath. After termination of incubation, tissue was rinsed and saponified, 
lipids were extracted with petroleum ether, and the radioactive count of extracted lipids 
was determined (Bauman et al., 1970). 20 
 
RNA extraction and quantitative RT-PCR 
Total RNA was extracted from approximately 30 mg of mammary tissue from 
each dam using the RNeasy Lipid Kit (Qiagen) with on-column DNase treatment 
(RNase-Free DNase Set; Qiagen) to remove DNA contamination. RNA concentration 
and integrity were determined by an Agilent 2100 BioAnalyzer (Agilent Technologies). 
The extracted RNA was reverse transcribed using SuperScript III First Strand Synthesis 
kit (Invitrogen) with random primers. Quantitative reverse transcriptase-PCR (qRT-PCR) 
reactions were conducted according to Harvatine and Bauman (2006) using Power SYBR 
Green (Applied Biosystems) and 400 nM of gene specific forward and reverse primers 
(Invitrogen; Appendix, Table 1). Sample message level was determined relative to a 
dilution curve of pooled cDNA (ABI Prism, 2001) and analyzed relative to the 
housekeeping gene ß2-microglobulin (B2M; Vandesompele et al., 2002). 
 
Statistical analysis 
Data were analyzed using the fit model procedure of JMP
® (Version 7.0, SAS 
Institute). The model included the fixed effects of genotype (WT and S14 KO) and 
treatment (CON and CLA), and the interaction of genotype and treatment. Effects of 
genotype and CLA were considered significant when P < 0.05, and interactions were 
considered significant when P < 0.1. The average litter weight gain for the two days 
immediately prior to CLA treatment was used as a covariant for litter weight gain. The 
average intake for the two days immediately prior to CLA treatment was used as a 
covariant for feed intake. The average initial weight of the dams was used as a covariant 21 
 
for liver weight. Data points with Studentized Residuals greater than 2.75 were 
considered outliers and excluded from analysis.  
 
 
RESULTS 
 
Performance parameters 
Litter weight gain during the last 3 days of treatment was decreased by both S14 deletion 
and CLA treatment (P = 0.05 and 0.01, respectively; Table 1). CLA treatment caused a 
28% reduction in litter weight gain in pups of S14 KO dams and no significant decrease 
in litter weight gain in pups of WT dams, but there was no interaction of genotype and 
CLA treatment (P = 0.25). CLA treatment reduced feed intake and weight gain of dams 
regardless of genotype (P = 0.01 and P < 0.001, respectively). Intake was decreased 13% 
in WT dams with CLA treatment, but there was no significant decrease in KO dams in 
response to CLA. Neither an effect of genotype nor an interaction of genotype and CLA 
was observed (P = 0.40 and 0.24, respectively). CLA treatment decreased dam weight 
gain in both genotypes; neither a genotype effect nor an interaction was observed (P = 
0.31 and 0.46, respectively). Liver weights were unaffected by either genotype or CLA 
treatment (P = 0.87 and 0.68, respectively).  
 
Milk clot fat content and composition 
Milk clots from pups nursing on S14 KO dams had 15.9% less fat than the milk 
clots from WT dams (P < 0.001; Table 2). CLA treatment also caused a reduction in  22 
 
Table 1. Effect of trans-10, cis-12 conjugated linoleic acid (CLA) on performance of 
lactating C57BL/6J wildtype and S14 null mice 
   Treatment
1  
  ------WT------ ----S14  KO----   P
2
  CON   CLA  CON   CLA  SE
M 
S14 CLA  int 
Litter weight gain, g/d
3  2.31  2.06  2.19  1.58  0.16  0.05 0.01 0.25 
Intake, g/d
4  14.2  12.3  13.2  12.4  0.50  0.40 0.01 0.24 
Dam weight gain, g/d  2.3 0.5  1.7  0.4  0.38  0.31  <.001  0.46 
Dam liver weight, g
5  2.20  2.18  2.21  2.18  0.10  0.87 0.68 0.99 
 
1Treatments were arranged in a 2x2 factorial design. Wildtype (WT) and S14 knockout (KO) 
mice were treated with either water (CON) or 3.5 mg/d trans-10, cis-12 conjugated linoleic acid 
(CLA). Litter weight gain, feed intake, and dam weight gain are based on the average of the last 3 
days of treatment. Values are LS means; n = 7 for WT CON, n = 9 for KO CLA, and n = 8 for 
WT CLA and KO CON.  
2The probability of a main effect of genotype (S14) and trans-10, cis-12 CLA (CLA) and the 
interaction of genotype and CLA (int).  
3The average litter weight gain for the two days immediately prior to CLA treatment was used as 
a covariant. 
4 The average intake for the two days immediately prior to CLA treatment was used as a 
covariant. 
5 The average initial weight of the dams was used as a covariant. 
 
 
milk clot fat percent (P = 0.02), but there was no interaction of genotype and CLA 
treatment (P = 0.11). CLA was not detected in the fatty acids of the milk clots of CON 
dams, but constituted 0.12% and 0.16% of milk clot fatty acids of WT CLA and KO CLA 
dams, respectively. CLA treatment caused a reduction in the de novo synthesized medium 
chain fatty acids C12:0, 14:0, and 14:1 (P <0.001), and an interaction of genotype and 
CLA was observed for each of these fatty acids (P < 0.1). Examination of the fatty acid 
data indicates that the KO mice were more responsive to the CLA treatment than the WT 
mice. The C16:0 component, which includes preformed and de novo fatty acids, was also 
significantly reduced by CLA (P = 0.009), although there was no interaction (P = 0.61). 
CLA treatment increased cis-C16:1 fatty acids in milk clots from KO dams. Both S14 23 
 
Table 2. Effect of trans-10, cis-12 conjugated linoleic acid (CLA) on milk clot fat 
concentration and fatty acid profile of C57BL/6J wildtype and S14 null mice 
 Treatment
1   
  -------WT------- -----S14  KO-----    P
2 
  CON CLA  CON  CLA  SEM S14 CLA int 
Milk clot fat, %  51.73 46.06 41.67 40.57 1.43 <.001 0.02 0.11
 
Fatty acid profile, g/100 g total fatty acids 
  8:0  0.07 0.05      0.09 0.08  0.02 0.38  0.63 0.70
  10:0    3.92  3.53  3.84  3.38  0.42 0.77  0.29 0.93
  12:0  10.21 9.99  8.52 6.32  0.32 <.001  <.001 0.003
  14:0  12.40 11.04 7.81  5.21 0.30 <.001  <.001 0.04
  14:1     0.10  0.07  0.09  0.08  0.01 0.50  <.001 0.03
  16:0  23.43  21.92 16.93   15.89  0.47 <.001 0.009 0.61
  16:1, cis    1.23 1.20  1.62 2.14  0.10 <.001  0.01   0.007
  18:0     2.32  2.63  1.86  2.16  0.05 <.001  <.001 0.93
  18:1, cis-9  14.56 17.16  20.62  23.89 0.59 <.001  <.001 0.56
  18:1, cis-13     1.92  2.25  3.03  3.31  0.08 <.001  <.001 0.70
  Linoleic acid  21.42    21.74  22.76  24.97  0.44 <.001  0.006 0.04
  Linolenic acid     1.90  1.91  2.14  2.19  0.05 <.001  0.54 0.64
  trans-10, cis-12 CLA     0.00  0.11  0.00  0.16  0.02 0.15  <.001 0.15
  20:2    1.25  1.13  1.65  1.51  0.05 <.001  0.01 0.83
  20:3  0.77 0.78  1.18 1.21  0.03 <.001  0.53 0.86
  20:4  0.79 1.03  1.17 1.75  0.07 <.001  <.001 0.02
  20:5  0.29 0.33  0.34 0.29  0.04 0.95  0.83 0.27
  22:4  0.32 0.32  0.58 0.66  0.03 <.001  0.13 0.19
  22:5  0.37 0.36  0.54 0.60  0.02 <.001  0.14 0.06
  22:6  0.31 0.32  0.36 0.39  0.02 0.003  0.30 0.55
 
Desaturase index 
           
  14:1/ (14:0 + 14:1)  0.008 0.006 0.011 0.015 .001 <.001 0.15 <.001
  16:1/ (16:0 + 16:1)  0.050 0.052 0.090 0.129 .004 <.001 <.001 0.002
 
1Treatments were arranged in a 2x2 factorial design. Wildtype (WT) and S14 knockout (KO) 
mice were treated with either water (CON) or 3.5 mg/d trans-10, cis-12 conjugated linoleic acid 
(CLA). Values are LS means; n = 8 for WT CON, n = 7 for KO CON, and n = 9 for WT CLA and 
KO CLA.  
2The probability of a main effect of genotype (S14) and trans-10, cis-12 CLA (CLA) and the 
interaction of genotype and CLA (int).  
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Figure 2. Effect of trans-10, cis-12 conjugated linoleic acid (CLA) on milk clot fatty acid 
profile by carbon length from C57BL/6J wildtype (WT) and S14 knockout (KO) mice 
Mice were treated with either water (CON) or 3.5 mg/d trans-10, cis-12 conjugated linoleic acid 
(CLA). Values are LS means ± SE, n = 7 – 9. 
 
deletion and CLA caused a reduction in C18:0 (P < 0.001 for both), but both caused an 
increase in cis-9 C18:1 and cis-13 C18:1 (P < 0.001 for all). This may be due to an 
increase in SCD activity. Both S14 deletion and CLA treatment caused an increase in the 
percentage of most of the long chain fatty acids, but interaction was not observed for 
most of these. The increase in the percentage of long chain fatty acids is not so much due 
to an increase in the amount of these fatty acids, but rather to the decrease in the amount 
of the short chain and medium chain fatty acids thereby resulting in an increase in the 
proportion of long chain fatty acids.  
A summary of the fatty acid profile according to carbon length makes more 
obvious the effect of genotype and CLA on de novo vs preformed fatty acids (Figure 2). 
At this low CLA dose, KO dams had a 28.7% reduction in the percentage of de novo fatty 
acids less than 16 carbons in length, whereas in WT dams this reduction (8.9%) was not 25 
 
  
Figure 3. Effect of trans-10, cis-12 conjugated linoleic acid (CLA) on rate of lipogenesis of 
mammary tissue explants from C57BL/6J wildtype (WT) and S14 knockout (KO) mice. 
Lipogeneiss was based on incorporation on 
14C glucose into fatty acids. Mice were treated with 
either water (CON) or 3.5 mg/d trans-10, cis-12 conjugated linoleic acid (CLA). Values are LS 
means ± SE, n = 7 – 9. 
 
significant. There was a significant interaction of genotype and CLA for the percentage 
of <C16 fatty acids (P = 0.04). The proportion of preformed (>C16) fatty acids increased 
with both S14 deletion and CLA treatment (P < 0.001, Table 2), but there was no 
interaction (P = 0.32).  
  SCD activity as determined by the desaturase indexes was significantly higher in 
KO dams relative to WT dams (P < 0.001). For both C14 and C16 desaturase indexes, 
there was a significant interaction of genotype and CLA treatment (P < 0.001 and P = 
0.002, respectively). 
 
Mammary lipogenic capacity 
  Mammary lipogenic capacity as determined by incorporation of 
14C glucose into 
fatty acids in tissue explants was decreased by both S14 deletion and CLA treatment (P =  26 
 
 
Figure 4. Effect of trans-10, cis-12 conjugated linoleic acid (CLA) on mammary expression 
of select lipogenic genes of C57BL/6J wildtype (WT) and S14 knockout (KO) mice..  
Mice were treated with either water (CON) or 3.5 mg/d trans-10, cis-12 conjugated linoleic acid 
(CLA). Values are LS means ± SE, n = 7-9. The expression level of wildtype controls (WT CON) 
was normalized to 100 for each gene. 
 
0.003 and 0.0003, respectively; Figure 3). However, no interaction of genotype and CLA 
treatment was observed (P = 0.93). 
 
Mammary gene expression 
  Mammary expression of S14 was at background for KO dams (Figure 4) and 
much lower than WT dams (P < 0.0001). Surprisingly, S14 mRNA level significantly 
increased in response to CLA in WT mice. No statistical difference was observed for any 
of the other genes.  
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DISCUSSION 
  Consistent with our previous studies, CLA treatment reduced litter weight gain, 
feed intake, and dam weight gain. Since milk fat synthesis was reduced due to CLA, 
dams required less energy for mammary lipogenesis and this is consistent with the 
reduction in feed intake. The reduction of fat in the milk clots in response to CLA most 
likely caused the decrease in litter weight gain that would occur as a result of reduced 
energy intake. S14 deletion caused a decrease in litter weight gain but not in feed intake 
or dam weight gain. As with previous studies, KO dams had reduced mammary lipogenic 
capacity, resulting in decreased percentage of de novo fatty acids out of total milk clot fat. 
Probably due to the low dose used in the current experiment, an interaction of genotype 
and CLA was observed for percent de novo fatty acids and for many individual fatty 
acids, but not for the performance data or for mammary lipogenic capacity. Consistent 
with our previous study, KO dams showed a greater increase in SCD activity than WT 
dams as determined by desaturase indexes.  
  Mammary tissue expression of lipogenic genes did not differ between WT and 
KO mice, except for S14. This is consistent with the results of our previous study with 
KO mice (Harvatine, Tanino, and Bauman, unpublished) and with the results from Zhu et 
al. (2005). Similarly, CLA appears to be inhibiting mammary lipogenesis by mechanisms 
other than the regulation of lipogenic gene expression. Surprisingly, CLA caused an 
increase in S14 mRNA level in the WT, rather than the expected coordinated 
downregulation of lipogenic gene expression. This contradicts with our previous result 
with the 20 mg/d dose of CLA, in which CLA treatment decreased mammary S14 mRNA 
level in WT mice. The reason for the increased S14 transcription is not apparent. 28 
 
 
Figure 5. Dose-dependent effect of trans-10, cis-12 conjugated linoleic acid (CLA) in the 
percent reduction of mammary de novo fatty acid synthesis in wildtype (WT) and S14 
knockout (KO) C57BL/6J mice.  
Data points are from the current experiment and from previous experiments in our laboratory 
(Harvatine, Tanino, and Bauman, unpublished). Data points were fit with a best-fit polynomial 
equation. R
2= 0.999 for WT and R
2= 0.973 for KO.  
 
The results suggest overall that the S14 null mouse has a greater reduction in 
lipogenesis in response to the low dose of CLA than WT, although the mechanism 
remains far from clear. When combined with data from previous experiments in our lab 
investigating WT and KO mice, it seems that the S14 null mice show dose-
responsiveness with similar sensitivity, rather than hypersensitivity (Figure 5). From the 
limited number of data points currently available, the ED50 (effective dose at half-
maximal response) for the WT mouse is estimated to be around 6 mg/d. The ED50 for the 
KO mouse seems to be around 5 mg/d. The similar ED50 of the two curves suggest that 
the lactogenic response to CLA of the WT and KO mice are similar in sensitivity. The 
results from this study also suggest that lack of S14 does not affect the dose-
responsiveness of other factors involved in CLA-induced inhibition of milk fat synthesis.  29 
 
Much remains unknown about the role of S14 in the lactogenic response to CLA. 
Previous studies have suggested that S14 functions as a transcriptional coactivator of 
lipogenic enzymes (Chou et al., 2008). However, the S14 null mouse did not show a 
downregulation of these genes in mammary tissue in previous studies (Zhu et al., 2005, 
Harvatine, Tanino, and Bauman, unpublished) and in the present study. The 
hyperresponsiveness of the S14 null mouse to CLA suggests that the S14 protein may 
play an indirect role in lipogenesis, possibly by altering the response of another factor 
involved in milk fat synthesis. For instance, S14 may repress an inhibitor of lipogenic 
gene transcription. This would be consistent with the localization of S14 in the nucleus 
and its putative lipogenic effect. However, it is not consistent with the lack of change in 
gene expression in the knockout mice.  
Alternatively, S14 may be regulating protein activity. Support for this comes from 
our interactions, in which we recently learned that a group at University of Texas 
Southwestern Medical Center has found that the S14 related protein (Mig 12) appears to 
play a role in catalyzing conversion of ACC to the polymeric form and in the interaction 
between ACC and FAS. Given the significant sequence homology between Mig 12 and 
S14, a similar role may be played by S14. To investigate this potential function of S14, 
the amount of polymeric ACC should be analyzed in the mammary tissue samples of the 
current experiment. This can be done either by a native Western blot which distinguishes 
the polymeric and protomeric forms of ACC by molecular weight, or by the use of avidin, 
which inactivates protomeric ACC but does not affect polymeric ACC activity (Ashcraft 
et al., 1980). If CLA treatment is found to decrease the amount of polymeric ACC in WT 
but not in S14 null mice, then S14 likely has a role in ACC polymerization. This possible 30 
 
function of S14 would explain the lower milk fat and lack of change in mammary gene 
expression in S14 null mice. Nevertheless, it would not explain the hyperresponsiveness 
of the S14 null mice to CLA. Much of the lactogenic response of the S14 null mouse to 
CLA, therefore, would still remain in question. Further investigation of the role of S14 in 
CLA-induced MFD will provide insight into possible solutions to MFD in the dairy cow, 
as well as the other biological roles of CLA.31 
 
APPENDIX 
Table 1. Murine primers used in quantitative RT-PCR analysis 
 
1Primer sequences from RTprimerDB (Pattyn et al., 2006) 
2Primer sequences from Primer bank (30911099a3; Wang et al., 2003) 
3Primer sequences from Hegarty et al. (2005) 
 
Gene/Primers  Sequence   Length  Accession No. 
B2M
1   166  NM_009735 
  51.F  CATGGCTCGCTCGGTGACC    
  216.R  AATGTGAGGCGGGTGGAACTG    
FASN
2   158  NM_007988 
  891.F  AGAGATCCCGAGACGCTTCT    
  1048.R  GCCTGGTAGGCATTCTGTAGT    
S14   117  NM_009381 
  283.F  TGAGAACGACGCTGCTGAAAC    
  399.R  AGGTGGGTAAGGATGTGATGGAG    
SCD1   102  NM_009127 
  113.F  TGGGAAAGTGAGGCGAGCAACTG    
  214.R  AGGGAGGTGCAGTGATGGTGGTG    
SREBP1c
3      
  96.F  GGAGCCATGGATTGCACATT    
  198.R  GCTTCCAGAGAGGAGGCC    32 
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